Navigating the Intersection of Gene Therapy and Drug Pricing.

Gene therapies, including CRISPR-based treatments, have the potential to revolutionize medicine, but their high cost puts them out of reach for many who need them. Researchers and health economists must work with industry and governments to find a more affordable funding model. Technological solutions such as streamlining production and testing of treatments and developing gene-therapy platforms could help improve accessibility, but pricing, regulation, and intellectual property debates must also be addressed.